Is Cerevel Therapeutics Holdings, Inc. (CERE) a Buy, Sell, or Hold?
Cerevel Therapeutics Holdings, Inc.
NASDAQ:CERE
$44.96 USD
$0.33 (0.74%)
- Volume
- 15.03M
- Average Volume
- 2.11M
- Market Capitalization
- $8.19B
- P/E Ratio
- -16.84
- Dividend Yield
- 0.00%
- Price Target
- $33.50
- Year High
- $44.99
- Year Low
- $19.59
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.92
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Ronald C. Renaud Jr., |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CERE |
| CUSIP | 15678U128 |
| CIK | 0001805387 |
| Web | https://www.cerevel.com |
| Phone | 844 304 2048 |
| Currency | USD |
| Employees | 355 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.71 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.92 |
| Quick Ratio | 10.92 |
| Cash Ratio | 10.75 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.14 |
| Price / Cash Flow | -23.67 |
| Price / Book | 10.81 |
Price Target and Rating
| Average Stock Price Forecast | $33.50 |
| High Stock Price Forecast | $40.00 |
| Low Stock Price Forecast | $27.00 |
| Forecast Upside/Downside | 34.21% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.67 |
| Trailing P/E Ratio | -16.84 |
| PEG Ratio | 2.48 |
| P/E Growth | 2.48 |
| Net Income | $-432.84M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -72.44% |
| Return on Assets | -34.81% |
Financials Score
| AltmanZ Score | 6.31 |
| Piotroski Score | 3.00 |
| Working Capital | 775.47M |
| Total Assets | 1.13B |
| Ebit | -461.13M |
| Market Cap | 8.19B |
| Total Liabilities | 562.89M |
Poll Results
About Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Stock
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine ... D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Frequently Asked Questions
-
What is the current Cerevel Therapeutics Holdings, Inc. (CERE) stock price?
-
Cerevel Therapeutics Holdings, Inc.(NASDAQ:CERE) stock price is $44.96 in the last trading session. During the trading session, CERE stock reached the peak price of $44.99 while $19.59 was the lowest point it dropped to. The percentage change in CERE stock occurred in the recent session was 0.74% while the dollar amount for the price change in CERE stock was $0.33.
-
CERE's industry and sector of operation?
-
The NASDAQ listed CERE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CERE?
-
Mark Bodenrader | Senior Vice President of Finance & Chief Accounting Officer
John J. Renger | Chief Scientific Officer
N. Anthony Coles Jr. | Executive Chairman
Kenneth A. DiPietro | Chief Human Resources Officer
Paul D. Burgess | Chief Business Development & Strategic Operations Officer -
How many employees does CERE have?
-
Number of CERE employees currently stands at 355. CERE operates from 222 Jacobs Street, Cambridge, MA 02141, US.
-
Link for CERE official website?
-
Official Website of CERE is: https://www.cerevel.com
-
How do I contact CERE?
-
CERE could be contacted at phone #844 304 2048 and can also be accessed through its website. CERE operates from 222 Jacobs Street, Cambridge, MA 02141, US.
-
How many shares of CERE are traded daily?
-
The average number of CERE shares traded daily for last 3 months was 2.11M.
-
What is the market cap of CERE currently?
-
The market value of CERE currently stands at $8.19B with its latest stock price at $44.96